|
Daily Medical Update
Qualitative defects of platelet function
Monday, July 13, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Hamostaseologie (2025) - Practice Guideline
Key Findings
- The updated guideline increases diagnostic consistency by combining standardized bleeding questionnaires, patient history, light transmission aggregometry, flow cytometry, and genetic testing.
- Standardized pre-analytic handling is expected to reduce unreliable platelet function results and increase diagnostic accuracy across inherited platelet disorder subtypes.
📋 Practice Implication: Use the guideline as a structured diagnostic pathway for suspected inherited platelet disorders, pairing functional assays with genetics rather than relying on isolated aggregation results.
|
Journal of thrombosis and haemostasis : JTH (2026) - Multicenter Study
Key Findings
- 100% of participating laboratories correctly diagnosed MYH9-related disease, Bernard-Soulier syndrome, Glanzmann thrombasthenia, and GFI1B-related thrombocytopenia using the shared immunofluorescence panel.
- Diagnostic sensitivity was reduced but still useful for TUBB1-related disorder, quantitative delta-storage pool disorder, and GATA1-related thrombocytopenia, with 5 to 6 of 7 laboratories identifying these entities.
📋 Practice Implication: Add blood-smear immunofluorescence phenotyping when structural inherited platelet disorders are suspected, especially as an adjunct that can narrow genetic and functional testing.
|
Injury (2025) - Multicenter Study
Key Findings
- 70% of severely injured bleeding trauma patients had platelet hypofunction in at least one Multiplate channel at presentation.
- Reduced ASPI, ADP, and TRAP platelet function parameters were associated with transfusion requirements and clinical outcomes beyond what standard coagulation tests captured.
📋 Practice Implication: In major trauma hemorrhage, consider early whole-blood platelet function testing when available to identify hypofunction that may influence hemostatic resuscitation.
|
International journal of stroke : official journal of the International Stroke Society (2025) - Systematic Review
Key Findings
- CYP2C19 loss-of-function alleles were associated with reduced clopidogrel effectiveness for secondary prevention of major ischemic events.
- Alternative antiplatelet strategies for loss-of-function carriers showed inconsistent improvement across randomized trial evidence, while major bleeding remained an important safety outcome.
📋 Practice Implication: For secondary prevention patients at high ischemic risk, CYP2C19 results can inform clopidogrel choice, but treatment changes should account for mixed trial evidence and bleeding risk.
|
Journal of vascular surgery (2025) - Systematic Review
Key Findings
- Poor clopidogrel response occurred in 43.2% of patients by genotyping and 23.2% by platelet function testing after noncoronary endovascular procedures.
- Poor responders had higher ischemic complication rates than normal responders, with odds ratios of 2.8 by genotyping and 6.3 by platelet function testing.
📋 Practice Implication: After noncoronary endovascular intervention, genotype or platelet function testing may help identify patients whose residual platelet reactivity leaves them vulnerable to stent thrombosis or restenosis.
|
|
💡
Summary
Recent evidence emphasizes better diagnostic standardization for inherited and acquired qualitative platelet dysfunction, including updated inherited platelet disorder algorithms and reproducible immunofluorescence phenotyping. Clinically relevant acquired dysfunction remains prominent in trauma and antiplatelet therapy, where platelet hypofunction or poor clopidogrel response was associated with transfusion needs, ischemic complications, and genotype-linked treatment uncertainty.
|
|